MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) has launched the world's first AI-powered voice analytics system designed to detect drug and alcohol impairment in real time for workplace safety. The technology, initially targeting the South American mining sector, aims to address the persistent challenge of ensuring workers operating heavy machinery or performing safety-critical tasks are not impaired by substances.
Workplace substance misuse costs U.S. employers over $81 billion annually through lost productivity, accidents, healthcare costs, and liability. Studies indicate that up to 40% of industrial workplace fatalities involve alcohol misuse. MindBio's voice-based AI system can identify signs of impairment within seconds, offering a non-invasive alternative to traditional biological testing methods.
The company, which has conducted extensive research into intoxication detection, is deploying the system in the mining sector where heavy machinery and remote operations make safety monitoring critical. The technology has broader relevance to a global market spanning safety-sensitive industries including mining, construction, and aviation.
Industrial employers across the world face a persistent challenge in monitoring impairment among workers. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is addressing that problem with artificial intelligence-driven speech analysis. The biotechnology company has developed a voice-based AI system designed to identify signs of alcohol or drug impairment within seconds, the first of its kind in the world.
The announcement highlights the growing intersection of AI technology and workplace safety. By leveraging voice analytics, MindBio offers a tool that can be deployed in remote or hazardous environments where traditional testing may be impractical. The system's ability to provide rapid results could help employers reduce accidents and liability while maintaining productivity.
For more information, visit the company's newsroom at https://ibn.fm/MBQIF.
